[The effect of early fluvastatin therapy on inflammatory factors in acute coronary syndrome].
OBJECTIVE
To investigate the effects of different doses of fluvastatin on serum levels of high-sensitive C-reactive protein (hs-CRP) and tumour necrosis factor-alpha (TNFalpha) in the early phase of acute coronary syndrome (ACS).


METHODS
Fifty eight patients with ACS were randomly separated into three groups. 20 patients in group A were given routine therapy, 20 patients in group B were given routine therapy with oral fluvastatin 40 mg once daily for 1 week and 18 patients in group C received routine therapy with oral fluvastatin 80 mg once daily for 1 week. 20 patients with stable coronary heart disease served controls. The serum levels of hs-CRP and TNFalpha before and after therapy were measured with immunoturbidimetric assay and ELISA method.


RESULTS
(1) The serum levels of hs-CRP and TNFalpha in the patients with ACS were significantly higher than those in the control group (P < 0.05). (2) The serum levels of hs-CRP and TNFalpha significantly lowered after one week of therapy in the two fluvastatin treated groups (P < 0.01 in all), especially in the 80 mg fluvastatin group, while no significant difference was observed before and after treatment in the routine therapy group. (3) The serum levels of hs-CRP and TNFalpha had a significant positive correlation in the patients with ACS (r = 0.70, P < 0.01), but no relationship were observed between TC, TG, LDL-C, or HDL-C and hs-CRP or TNFalpha by Pearson correlation analysis.


CONCLUSIONS
The serum levels of inflammatory factors including CRP and TNFalpha are increased in patients with ACS and early fluvastatin intervention may decease dose-dependently the serum levels of hs-CRP and TNFalpha. The anti-inflammatory effect of fluvastatin may be beyond that of lipid lowering. Early intensive fluvastatin treatment may yield more significant benefits in the patients with ACS.
Yang
Jun
J
Department of Cardiology, the Second Xiangya Hospital of Central South University, Changsha 410011, China.
Li
Xiang-ping
XP
Zhao
Shui-ping
SP
Li
Jiang
J
Li
Jing-dong
JD
Xie
Xiao-ming
XM
Peng
Jun
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D002097:C-Reactive Protein / Q000378:metabolism; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage*; D005260:Female; D000077340:Fluvastatin; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D007249:Inflammation / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000924:Anticholesteremic Agents; D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D008055:Lipids; D014409:Tumor Necrosis Factor-alpha; D000077340:Fluvastatin; D002097:C-Reactive Protein